ketorolac has been researched along with Vascular Diseases in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The MQS score accounted for variations in the types of analgesic medications, routes of administration, dosing schedules, and opioid dosing requirements." | 1.34 | Quantification of analgesic use in children with sickle cell disease. ( Beyer, JE; Jacob, E; Miaskowski, C; Savedra, M; Styles, L; Treadwell, M, 2007) |
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | 1.28 | Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sitkin, SI | 1 |
| Davydova, OB | 1 |
| Kostin, IO | 1 |
| Gasparian, AL | 1 |
| de Franceschi, L | 1 |
| Finco, G | 1 |
| Vassanelli, A | 1 |
| Zaia, B | 1 |
| Ischia, S | 1 |
| Corrocher, R | 1 |
| Jacob, E | 1 |
| Miaskowski, C | 1 |
| Savedra, M | 1 |
| Beyer, JE | 1 |
| Treadwell, M | 1 |
| Styles, L | 1 |
| Sanders, DY | 1 |
| Severance, HW | 1 |
| Pollack, CV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis[NCT00094887] | Phase 2 | 150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospitalization is defined as the length of time from admission to discharge order (NCT00094887)
Timeframe: within 40 days
| Intervention | Days (Median) |
|---|---|
| Inhaled Nitric Oxide | 4.06 |
| Placebo | 3.11 |
(NCT00094887)
Timeframe: within 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 5 |
| Placebo | 7 |
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia (NCT00094887)
Timeframe: within 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 8 |
| Placebo | 7 |
"VOC resolution was defined by all of the following conditions:~Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best)~Freedom from parenteral narcotic use,~Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis,~Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment." (NCT00094887)
Timeframe: within 30 days
| Intervention | Hours (Median) |
|---|---|
| Inhaled Nitric Oxide | 61.83 |
| Placebo | 55.16 |
The number of participants readmitted to the hospital for any reason within 30 days after discharge (NCT00094887)
Timeframe: during first 24 hours and during 30 day follow-up
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| during first 24 hours | during 30-day follow-up | |
| Inhaled Nitric Oxide | 0 | 9 |
| Placebo | 0 | 17 |
The total dose (mg) of opioid medications received during the trial (NCT00094887)
Timeframe: within 8 hours and within 40 days
| Intervention | mg (Median) | |
|---|---|---|
| within 8 hours | within 40 days | |
| Inhaled Nitric Oxide | 16.25 | 153.75 |
| Placebo | 17.25 | 211.37 |
1 trial available for ketorolac and Vascular Diseases
| Article | Year |
|---|---|
[Use of analgesia and sedation in dental implantology in patients with concomitant hypertension].
Topics: Anesthesia, Dental; Anesthesia, Local; Blood Pressure; Conscious Sedation; Dental Implantation; Fema | 2015 |
3 other studies available for ketorolac and Vascular Diseases
| Article | Year |
|---|---|
A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain.
Topics: Adolescent; Analgesics; Anemia, Sickle Cell; Child; Child, Preschool; Combined Modality Therapy; Cyt | 2004 |
Quantification of analgesic use in children with sickle cell disease.
Topics: Adolescent; Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammatory Agents, No | 2007 |
Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics; Anemia, Sickle Cell; Anti-Inflammatory | 1992 |